Last updated: April 25, 2026
Who Supplies Drospirenone and Estetrol for Pharmaceutical Drug Products?
What are the key supplier profiles for drospirenone and estetrol?
Drospirenone and estetrol are supplied through two main procurement channels: (1) active pharmaceutical ingredient (API) manufacturers and (2) finished-dosage or intermediate suppliers that support drug product manufacturing. For business planning, the actionable split is between API supply (commercial API and development-grade API) and intermediates/contract manufacturing (CMP and CMO routes).
Because “suppliers” can mean different contract positions (API, intermediate, or finished dose), the supplier list below is structured by API manufacturing and known CMO/CDMO support patterns rather than retail “distributors,” which typically add no manufacturing capability.
Who supplies drospirenone (API and key manufacturing ecosystem)?
Drospirenone is a widely used progestin in oral contraceptives and hormone therapies. Supplier coverage is typically broad across China and Europe, with additional sources tied to regulated-genric and branded contraceptive supply chains.
Typical drospirenone supplier archetypes used in procurement:
- Specialty steroid API manufacturers producing drospirenone via multi-step steroid chemistry.
- CMC-focused API producers supplying commercial and clinical batches.
- CDMOs with steroid-process capability (often providing late-stage intermediates, scale-up, and batch release support).
Procurement-ready checklist for drospirenone sourcing
- API status: commercial and/or clinical grade availability.
- Quality package: CEP or DMF/ASMF support.
- Supply chain: batch release and regulatory documentation cadence.
- Capacity: ability to support campaign manufacturing and stability commitments.
Who supplies estetrol (API and key manufacturing ecosystem)?
Estetrol (E4) is a naturally derived estrogen used in hormone therapy and oral contraceptive development. Supplier coverage is narrower than drospirenone because estetrol is more specialty and less commoditized.
Typical estetrol supplier archetypes used in procurement:
- Specialty estrogen API manufacturers producing estetrol with tightly controlled purification and crystallization processes.
- Development-focused suppliers that support clinical material through analytical method transfer and stability design.
- CMOs/CDMOs that can handle estrogen solids processing, form selection, and scale-up validation.
What supplier constraints matter most for drospirenone vs. estetrol?
| Attribute |
Drospirenone |
Estetrol |
| Commercial maturity |
Higher |
Lower |
| Supplier breadth |
Broader market coverage |
More limited niche coverage |
| Typical procurement bottleneck |
Regulatory file acceptance and campaign scheduling |
Solid form/process control and method transfer timelines |
| Common buyer requirement |
CEP/DMF readiness and supply continuity |
CMC documentation, analytical capability, and consistent polymorph control |
What are the most actionable supplier categories to target?
For drospirenone
- Tier-1 API manufacturers with regulatory-ready documentation (CEP/DMF/ASMF).
- Steroid-chemistry CDMOs offering intermediate supply and process development for early-phase or scale-up.
- EU/US/East-Asia qualified sources that can provide audit-ready quality systems for hormone APIs.
For estetrol
- Specialty estrogen API producers with demonstrated batch consistency.
- CMOs focused on estrogen solids and analytical method transfer (HPLC/GC impurity profiling, crystallization and polymorph control).
- Clinical and commercial campaign suppliers with proven stability and packaging controls.
How do you screen suppliers efficiently (requirements-driven)?
For hormone APIs, the supplier selection process should be evidence-based and fast. The decision gates below reflect typical regulatory and technical review points.
API quality gate
- Compliance documentation: CEP/DMF/ASMF availability
- Impurity profile control: known genotoxic and residual solvent limits aligned to intended routes
- Batch traceability: consistent CoA and specification history
CMC and manufacturing gate
- Capability to support scale-up without specification drift
- Stability readiness: stress and long-term packages to match intended shelf life
- Analytical method transfer readiness for clinical-to-commercial transition
Supply continuity gate
- Campaign capacity and ability to schedule repeat batches
- MOQ and lead times aligned to development stage
- Audit status for quality and change control
Key Takeaways
- Drospirenone sourcing typically has broader API supplier coverage due to higher commercial maturity, with the main friction points centered on regulatory file acceptance and supply scheduling.
- Estetrol sourcing has more niche, specialty coverage, with the main friction points centered on solids/process control, analytical method transfer, and consistent batch performance.
- The most actionable procurement path is to target API manufacturers and CDMOs with hormone-steroid/estrogen solids capability, then filter by CEP/DMF readiness, impurity control, stability package maturity, and campaign capacity.
FAQs
-
Do drospirenone and estetrol have different sourcing strategies?
Yes. Drospirenone is usually easier to source due to broader supplier breadth; estetrol typically needs a tighter qualification focus around solids and analytical consistency.
-
Is it better to buy estetrol as API only, or include intermediates/CDMO support?
Buyers typically reduce technical risk by using API suppliers that can support method transfer and solids/process reproducibility, which may include CDMO involvement depending on the development stage.
-
What documentation should suppliers provide for hormone APIs?
Expect CEP/DMF/ASMF readiness (where applicable), CoA with complete specifications, impurity data, and support for stability and analytical method transfer.
-
How should buyers evaluate supplier capacity?
Evaluate campaign capability, repeat-batch scheduling, lead time reliability, and the supplier’s change control history for validated processes.
-
What are the fastest paths to secure supply?
For drospirenone, use established API manufacturers with regulatory packages. For estetrol, prioritize suppliers with proven batch-to-batch consistency and established analytical capability for impurities and solids properties.
References (APA)
[1] United States Food and Drug Administration (FDA). Drug Approval Package search results for drospirenone and estetrol-related products. https://www.accessdata.fda.gov/
[2] European Medicines Agency (EMA). Public assessment reports and EPAR-related information. https://www.ema.europa.eu/
[3] World Health Organization (WHO). WHO prequalification and reference information for APIs and manufacturing. https://extranet.who.int/prequal/
